New shareholder loan

By

Regulatory News | 22 Nov, 2019

Updated : 11:32

RNS Number : 3906U
Cathay International Holdings Ld
22 November 2019
 

22 November 2019

 

Cathay International Holdings Limited

("Cathay" or the "Company")

 

New shareholder loan

 

Cathay International Holdings Limited (LSE: CTI.L) announces that it has agreed a new loan facility for USD 23 million from Cathay International EW No. 43 Limited, a company controlled by Mr Wu, the Chairman of the Company, on normal commercial terms.  The facility will be used to provide working capital for the Group.

The facility has an initial term of 1 year, interest is payable at the rate of LIBOR +3.5% per annum and is unsecured.  In addition, the loan is repayable in certain events of default or in the event that the Company raises capital through the sale of assets or otherwise.

- ENDS -

 

For further enquiries, please contact:

 

Cathay International Holdings Limited

Eric Siu (Finance Director)

Patrick Sung (Director and Controller)

 

 

Tel: +852 2828 9289

Consilium Strategic Communications

Mary-Jane Elliott / Matthew Neal / Lindsey Neville

 

 

Tel: +44 (0) 203 709 5702

 

 

About Cathay 

Cathay International Holdings Limited (LSE: CTI.L) is a main market listed investment holding company and an operator and investor in the healthcare sector in the People's Republic of China (the "PRC"). The Company and its subsidiaries (collectively the "Group") aim to leverage on investment opportunities in the growing domestic demand for high quality healthcare products in the PRC and build portfolio companies into market sector leaders with competitive edge. Cathay has already demonstrated a track record of identifying investment opportunities in this area including: Lansen, a leading specialty pharmaceutical company focused on rheumatology and dermatology in the PRC; Haizi, a company engaged in the manufacture, marketing and sale of inositol and its by-product, di-calcium phosphate; Natural Dailyhealth, a company engaged in production and sales of plant extracts for use as key active ingredients in healthcare products; and Botai, a company engaged in collagen products.

 

The Group employs approximately 1,500 people across the PRC, including over 20 specialist corporate and business development staff based at the holding company's offices in Hong Kong and Shenzhen. Cathay also has a hotel investment. For more information please visit the Company's website: www.cathay-intl.com.hk.

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCZMMZMMZNGLZM

Last news